DE69433394D1 - Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen - Google Patents

Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen

Info

Publication number
DE69433394D1
DE69433394D1 DE69433394T DE69433394T DE69433394D1 DE 69433394 D1 DE69433394 D1 DE 69433394D1 DE 69433394 T DE69433394 T DE 69433394T DE 69433394 T DE69433394 T DE 69433394T DE 69433394 D1 DE69433394 D1 DE 69433394D1
Authority
DE
Germany
Prior art keywords
cholinergically
modulation
botulinum toxins
controlled secretions
secretions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433394T
Other languages
English (en)
Other versions
DE69433394T3 (de
DE69433394T2 (de
Inventor
Roger K Aoki
Michael W Grayston
Steven R Carlson
Judith M Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22634387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69433394(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE69433394D1 publication Critical patent/DE69433394D1/de
Publication of DE69433394T2 publication Critical patent/DE69433394T2/de
Publication of DE69433394T3 publication Critical patent/DE69433394T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69433394T 1993-12-28 1994-12-16 Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen Expired - Lifetime DE69433394T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17399693A 1993-12-28 1993-12-28
US173996 1993-12-28

Publications (3)

Publication Number Publication Date
DE69433394D1 true DE69433394D1 (de) 2004-01-15
DE69433394T2 DE69433394T2 (de) 2004-10-14
DE69433394T3 DE69433394T3 (de) 2010-08-12

Family

ID=22634387

Family Applications (23)

Application Number Title Priority Date Filing Date
DE69435330T Expired - Lifetime DE69435330D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69434535T Revoked DE69434535T2 (de) 1993-12-28 1994-12-16 Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
DE69434443T Revoked DE69434443T2 (de) 1993-12-28 1994-12-16 Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
DE69435249T Expired - Lifetime DE69435249D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
DE69434008T Expired - Lifetime DE69434008T2 (de) 1993-12-28 1994-12-16 Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen
DE122009000038C Pending DE122009000038I1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69435116T Expired - Lifetime DE69435116D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen
DE122008000042C Pending DE122008000042I1 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE122008000043C Pending DE122008000043I1 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69433394T Expired - Lifetime DE69433394T3 (de) 1993-12-28 1994-12-16 Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
DE69435270T Expired - Lifetime DE69435270D1 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
DE69434540T Expired - Lifetime DE69434540T2 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69435302T Expired - Lifetime DE69435302D1 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
DE69435276T Expired - Lifetime DE69435276D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie
DE69435321T Expired - Lifetime DE69435321D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69435149T Expired - Lifetime DE69435149D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen
DE69427869T Expired - Lifetime DE69427869T2 (de) 1993-12-28 1994-12-16 Botulinumtoxine zur behandlung von hyperhydrosis
DE69435194T Expired - Lifetime DE69435194D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69434511T Expired - Lifetime DE69434511T2 (de) 1993-12-28 1994-12-16 Botulinumtoxin zur Behandlung von Dystonie
DE69434610T Expired - Lifetime DE69434610T2 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE69435243T Expired - Lifetime DE69435243D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE69428813T Expired - Lifetime DE69428813T2 (de) 1993-12-28 1994-12-16 Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
DE69434319T Expired - Lifetime DE69434319T3 (de) 1993-12-28 1994-12-16 Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen

Family Applications Before (9)

Application Number Title Priority Date Filing Date
DE69435330T Expired - Lifetime DE69435330D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69434535T Revoked DE69434535T2 (de) 1993-12-28 1994-12-16 Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
DE69434443T Revoked DE69434443T2 (de) 1993-12-28 1994-12-16 Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
DE69435249T Expired - Lifetime DE69435249D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
DE69434008T Expired - Lifetime DE69434008T2 (de) 1993-12-28 1994-12-16 Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen
DE122009000038C Pending DE122009000038I1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69435116T Expired - Lifetime DE69435116D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen
DE122008000042C Pending DE122008000042I1 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE122008000043C Pending DE122008000043I1 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie

Family Applications After (13)

Application Number Title Priority Date Filing Date
DE69435270T Expired - Lifetime DE69435270D1 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
DE69434540T Expired - Lifetime DE69434540T2 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69435302T Expired - Lifetime DE69435302D1 (de) 1993-12-28 1994-12-16 Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
DE69435276T Expired - Lifetime DE69435276D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie
DE69435321T Expired - Lifetime DE69435321D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69435149T Expired - Lifetime DE69435149D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen
DE69427869T Expired - Lifetime DE69427869T2 (de) 1993-12-28 1994-12-16 Botulinumtoxine zur behandlung von hyperhydrosis
DE69435194T Expired - Lifetime DE69435194D1 (de) 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69434511T Expired - Lifetime DE69434511T2 (de) 1993-12-28 1994-12-16 Botulinumtoxin zur Behandlung von Dystonie
DE69434610T Expired - Lifetime DE69434610T2 (de) 1993-12-28 1994-12-16 Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE69435243T Expired - Lifetime DE69435243D1 (de) 1993-12-28 1994-12-16 Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE69428813T Expired - Lifetime DE69428813T2 (de) 1993-12-28 1994-12-16 Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
DE69434319T Expired - Lifetime DE69434319T3 (de) 1993-12-28 1994-12-16 Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen

Country Status (9)

Country Link
EP (23) EP1147775B1 (de)
JP (33) JP3238154B2 (de)
AU (1) AU688452B2 (de)
CA (2) CA2180011C (de)
DE (23) DE69435330D1 (de)
ES (18) ES2355491T3 (de)
FR (1) FR08C0034I1 (de)
HK (6) HK1033274A1 (de)
WO (1) WO1995017904A2 (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
DE69435253D1 (de) 1993-06-10 2009-12-31 Allergan Inc Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
AU2007202480B2 (en) * 1993-12-28 2009-01-29 Allergan, Inc. Method for treating pain associated with a muscle disorder
EP1147775B1 (de) * 1993-12-28 2009-03-04 Allergan, Inc. Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8557256B2 (en) 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
EP1086702B1 (de) * 1994-05-09 2005-04-13 BINDER, William J. Präsynaptische Neurotoxine gegen Migränekopfschmerzen
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
US6780413B2 (en) 1996-09-19 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
AU2006225229B2 (en) * 1997-07-15 2006-12-07 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
AU2008201535C1 (en) * 1997-07-15 2013-09-12 Allergan, Inc. Use of neurotoxin therapy for treatment of urologic and related disorders
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
CA2505933C (en) * 1997-07-15 2008-09-30 Richard A. Schmidt Use of botulinum toxin for treating urinary incontinence
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
CA2319113A1 (en) 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
US8790897B2 (en) 1998-08-25 2014-07-29 Syntaxin Ltd. Treatment of mucus hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6977080B1 (en) * 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6524580B1 (en) * 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) * 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
AU2001276005A1 (en) * 2000-08-02 2002-02-13 Allergan Sales, Inc. Method for treating a neoplasm
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) * 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
KR20030018827A (ko) * 2001-08-31 2003-03-06 서구일 Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
KR20050061541A (ko) * 2002-10-15 2005-06-22 알러간, 인코포레이티드 보툴리눔 독소 치과 치료 및 시술
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
MXPA05009424A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento de chalazion cronico y hordeolum con la toxina botulinica.
KR20050109969A (ko) * 2003-03-06 2005-11-22 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 보툴리눔 톡신으로 부비동염 관련 만성 안면통 및 두통을치료하는 방법
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2857595B1 (fr) * 2003-07-18 2005-10-07 Sod Conseils Rech Applic Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7276244B2 (en) 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
DE602005001854T2 (de) * 2004-02-12 2008-04-17 Philip San Clemente Radovic Behandlung von abweichungen der ersten metatarsophalangealen verbindung des fusses
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8398997B2 (en) 2004-03-03 2013-03-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
JP2008531732A (ja) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
EP1747782A1 (de) 2005-07-19 2007-01-31 Cesare Montecucco Produkte zur topischen Anwendung enthaltend Lysophospholipide und Fettsäuren
US7910116B2 (en) 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
AU2006315117A1 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7655625B2 (en) 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
WO2008121067A1 (en) 2007-03-30 2008-10-09 Anders Fagergren Quantification of mechanical and neural contributions to spasticity
CA2694046C (en) 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
EP2072039A1 (de) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Verwendung eines neurotoxischen Bestandteils des Clostridium-botulinum-Toxinkomplexes zur Verringerung oder Verhütung von Nebenwirkungen
US8470337B2 (en) 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
NO2379104T3 (de) 2008-12-31 2018-07-28
WO2010151840A2 (en) 2009-06-25 2010-12-29 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
RU2545453C2 (ru) * 2013-03-21 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения переломов нижней челюсти
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
WO2016002984A1 (ko) * 2014-06-30 2016-01-07 (주)메디톡스 보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3843777A4 (de) * 2018-08-28 2022-05-04 Ira Sanders Therapeutika für die haut
RU2732204C1 (ru) * 2020-01-28 2020-09-14 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения головных болей напряжения по Гурову-Левину
KR20220046507A (ko) * 2020-10-07 2022-04-14 주식회사 프로톡스 보툴리눔 독소의 진공 건조 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
GB9022250D0 (en) * 1990-10-12 1990-11-28 Glaxo Group Ltd Medicaments
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JP3510886B2 (ja) * 1992-06-23 2004-03-29 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド ボツリヌスｂ複合体を含有する医薬組成物
WO1994015629A1 (en) * 1993-01-15 1994-07-21 Associated Synapse Biologics Method for treating myofascial pain syndrome
DE69435253D1 (de) * 1993-06-10 2009-12-31 Allergan Inc Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen
DE69432299T2 (de) * 1993-06-10 2003-12-11 Allergan Inc Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP1147775B1 (de) * 1993-12-28 2009-03-04 Allergan, Inc. Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP1086702B1 (de) * 1994-05-09 2005-04-13 BINDER, William J. Präsynaptische Neurotoxine gegen Migränekopfschmerzen
JP2001104991A (ja) * 1999-10-12 2001-04-17 Toyoaki Kubota 循環水の有機質除去剤

Also Published As

Publication number Publication date
JP2002114706A (ja) 2002-04-16
CA2682117A1 (en) 1995-07-06
DE69435243D1 (de) 2009-11-19
JP2006160756A (ja) 2006-06-22
DE69434610T2 (de) 2008-11-27
JP2008056682A (ja) 2008-03-13
ES2309973T3 (es) 2008-12-16
DE122008000042I1 (de) 2009-01-02
JP2002068989A (ja) 2002-03-08
ES2339865T3 (es) 2010-05-26
EP1072270A3 (de) 2002-08-07
DE122008000043I1 (de) 2008-11-20
JP2012197287A (ja) 2012-10-18
ES2246800T3 (es) 2006-03-01
JP2002087985A (ja) 2002-03-27
EP1010431B1 (de) 2005-03-30
DE69435276D1 (de) 2010-04-08
EP1103267B1 (de) 2004-09-15
EP1147775A3 (de) 2003-01-15
EP1563843B1 (de) 2013-08-07
DE69434511D1 (de) 2006-03-02
CA2180011C (en) 2001-05-15
DE69434319D1 (de) 2005-05-04
EP1005867B1 (de) 2003-12-03
EP1366771B1 (de) 2008-03-26
DE69435321D1 (de) 2010-12-16
DE69427869T2 (de) 2002-04-11
ES2355491T3 (es) 2011-03-28
HK1106700A1 (en) 2008-03-20
EP1502600A1 (de) 2005-02-02
JP2002087986A (ja) 2002-03-27
JPH09507234A (ja) 1997-07-22
EP1488803B1 (de) 2008-03-26
DE69435149D1 (de) 2008-11-20
JP2002087988A (ja) 2002-03-27
FR08C0034I1 (fr) 2008-09-26
DE69434443T2 (de) 2006-05-24
EP1790352B1 (de) 2008-07-09
JP2013006865A (ja) 2013-01-10
DE69433394T3 (de) 2010-08-12
EP1486214A1 (de) 2004-12-15
DE69434610D1 (de) 2008-08-21
EP1757325B1 (de) 2010-11-03
JP2008037877A (ja) 2008-02-21
HK1064599A1 (en) 2005-02-04
JP2012167116A (ja) 2012-09-06
JP2002087984A (ja) 2002-03-27
ES2340172T3 (es) 2010-05-31
ES2237033T3 (es) 2005-07-16
EP1366771A2 (de) 2003-12-03
DE69434511T2 (de) 2006-07-13
ES2248780T3 (es) 2008-06-16
HK1072375A1 (en) 2005-08-26
EP1421948B1 (de) 2008-10-08
EP1366771A3 (de) 2003-12-10
DE69433394T2 (de) 2004-10-14
EP1488803A1 (de) 2004-12-22
DE69434535T2 (de) 2006-07-20
EP1591129A3 (de) 2005-11-16
ES2207910T3 (es) 2004-06-01
WO1995017904A2 (en) 1995-07-06
DE69435194D1 (de) 2009-04-16
EP1005867B2 (de) 2010-02-17
EP0737074A1 (de) 1996-10-16
DE69427869D1 (de) 2001-09-06
ES2334357T3 (es) 2010-03-09
JP2002097156A (ja) 2002-04-02
EP1010431B2 (de) 2010-07-14
AU688452B2 (en) 1998-03-12
EP1600163B1 (de) 2010-02-17
DE69435270D1 (de) 2010-04-01
EP1147776A2 (de) 2001-10-24
EP1072270A2 (de) 2001-01-31
AU1516295A (en) 1995-07-17
EP1421948A2 (de) 2004-05-26
EP1790352A1 (de) 2007-05-30
JP2002104990A (ja) 2002-04-10
EP1366770A2 (de) 2003-12-03
HK1070831A1 (en) 2005-06-30
JP2012167117A (ja) 2012-09-06
EP1600163A1 (de) 2005-11-30
HK1033274A1 (en) 2001-08-24
ES2159624T3 (es) 2001-10-16
EP2027872B1 (de) 2010-07-14
ES2223393T3 (es) 2005-03-01
JP2002104991A (ja) 2002-04-10
EP1477183A1 (de) 2004-11-17
DE69428813D1 (de) 2001-11-29
CA2180011A1 (en) 1995-07-06
WO1995017904A3 (en) 1995-10-19
DE69434319T2 (de) 2006-03-09
EP1366770B1 (de) 2005-07-27
DE69434008T2 (de) 2005-09-22
DE69435249D1 (de) 2009-12-17
JP2010202660A (ja) 2010-09-16
ES2347384T3 (es) 2010-10-28
JP3238154B2 (ja) 2001-12-10
EP1421948A3 (de) 2004-06-16
EP1010431A3 (de) 2001-05-16
ES2332905T3 (es) 2010-02-15
DE69434319T3 (de) 2011-02-17
JP2002097145A (ja) 2002-04-02
DE69434540D1 (de) 2009-03-26
EP1477183B1 (de) 2005-11-02
JP2008031176A (ja) 2008-02-14
EP1147776B1 (de) 2010-12-15
JP2006160754A (ja) 2006-06-22
EP1010431A2 (de) 2000-06-21
EP1147775B1 (de) 2009-03-04
EP0770395B1 (de) 2001-10-24
ES2247575T3 (es) 2006-03-01
EP1072270B1 (de) 2005-10-19
EP1563843A1 (de) 2005-08-17
EP1591129A2 (de) 2005-11-02
DE69434535D1 (de) 2005-12-08
EP1757325A1 (de) 2007-02-28
EP1598077A1 (de) 2005-11-23
ES2163090T3 (es) 2002-01-16
JP2006160753A (ja) 2006-06-22
JP2006160755A (ja) 2006-06-22
DE122009000038I1 (de) 2009-11-05
DE69434540T2 (de) 2009-06-18
EP1602379A1 (de) 2005-12-07
EP1005867A3 (de) 2001-06-13
EP2027872A1 (de) 2009-02-25
ES2319860T3 (es) 2009-05-14
EP0770395A1 (de) 1997-05-02
DE69435330D1 (de) 2011-01-27
DE69428813T2 (de) 2002-04-04
JP2010202661A (ja) 2010-09-16
ES2251651T3 (es) 2008-07-16
EP1103267A1 (de) 2001-05-30
EP1147776A3 (de) 2003-01-15
JP2008063339A (ja) 2008-03-21
EP1366770A3 (de) 2004-03-17
EP1591129B1 (de) 2010-02-24
EP1502600B1 (de) 2009-10-07
DE69434008D1 (de) 2004-10-21
JP2012167115A (ja) 2012-09-06
JP2012167114A (ja) 2012-09-06
ES2242126T3 (es) 2005-11-01
JP2012188433A (ja) 2012-10-04
ES2237033T5 (es) 2010-10-29
DE69435116D1 (de) 2008-08-21
ES2207910T5 (es) 2010-05-21
EP1598077B1 (de) 2009-11-04
DE69435302D1 (de) 2010-08-26
JP2007262086A (ja) 2007-10-11
JP2010209105A (ja) 2010-09-24
JP2010202659A (ja) 2010-09-16
HK1071071A1 (en) 2005-07-08
JP2002087987A (ja) 2002-03-27
EP1147775A2 (de) 2001-10-24
EP0737074B1 (de) 2001-08-01
DE69434443D1 (de) 2005-09-01
JP2008056683A (ja) 2008-03-13
EP1005867A2 (de) 2000-06-07

Similar Documents

Publication Publication Date Title
DE69433394D1 (de) Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
DE69422575D1 (de) System zur Erklärung von Austellungsstücken
DE69435129D1 (de) Fernbedienung zur direkten Eingabe mit sequentiellem Kanalsuchlauf
DE69417546D1 (de) Einrichtung zur steuerung von squids
DE59508631D1 (de) System zur fahrstabilitätsregelung
DE69427716D1 (de) Klebeverband zur Blutstillung
DE59503335D1 (de) Informationssystem zur Produktionskontrolle
DE69407452T2 (de) Zugbeeinflussungsanlage
DE69427029T2 (de) Verfaheren zur verbrennungsmotorsteuerung
DE59403286D1 (de) Regelventil
DE69306721D1 (de) Handsteuerungsystem
DE69415868D1 (de) Kontrolleinheit zur Betätigung von Unterwasserventilen
DE69418801D1 (de) System zur Steuerung der Voreinspritzung
FI964909A (fi) Substituoidut aryylialkyylitioalkyylipyridiinit Helicobacter-bakteerien torjumiseksi
DE69412422T2 (de) Steuerventil
DE69406238T2 (de) Regelventil
DE69429476D1 (de) System zur automatischen Frequenzregelung
DE69402237D1 (de) Regelventil
DE69413250D1 (de) Regelventil
DE69423085D1 (de) Geräte zur Übertragung von Information
DE69413308D1 (de) Magneto-optisches Modulationssystem
DE69107246D1 (de) Einrichtung und Verfahren zur Verbesserung der Steuerung von Schaltnetzteilen.
DE9402438U1 (de) Distanzscheibe zur Spurverbreiterung
DE9314272U1 (de) Regelventil
DE9307944U1 (de) Steuereinheit zur Verteilung von Regenwasser

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings